Literature DB >> 8804354

Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level.

T Sohda1, K Yun, K Iwata, H Soejima, M Okumura.   

Abstract

To investigate the control mechanisms of insulin-like growth factor 2 (IGF2) gene expression, we studied 25 hepatocellular carcinomas (HCC) to compare the levels of total IGF2 mRNA and the IGF2 peptide by using in situ hybridization and immunohistochemistry, respectively. Increased expression of IGF2 mRNA and the IGF2 peptide was observed in 13 HCC. The spatial distribution and intensity of IGF2 mRNA in these 13 HCC was almost identical to that of the IGF2 peptide, which suggests that high IGF2 expression was primarily regulated at the transcriptional level. The levels of IGF2 gene expression in the 13 HCC seemed to be inversely correlated with the degree of tumor cell differentiation. Furthermore, in situ hybridization using probes specific to transcripts expressed from the IGF2 promoters P1 and P3 revealed that transcription was predominantly from P3 rather than from P1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804354

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

1.  Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

Authors:  Z R Fan; D H Yang; J Cui; H R Qin; C C Huang
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Authors:  Philippe Couvert; Alain Carrié; Jacques Pariès; Jenny Vaysse; Audrey Miroglio; Antoine Kerjean; Pierre Nahon; Jamel Chelly; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Ganne-Carrié
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.

Authors:  Jose Tadeu Stefano; Maria Lucia Correa-Giannella; Cristiane Maria Freitas Ribeiro; Venancio Avancini Ferreira Alves; Paulo Celso Bosco Massarollo; Marcel Cerqueira Cesar Machado; Daniel Giannella-Neto
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

Review 4.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

5.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

6.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Tatiana Birman; Ofer N Gofrit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2011-04-30

7.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

8.  Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver.

Authors:  Lisa Longato; Suzanne de la Monte; Noriyoshi Kuzushita; Masayoshi Horimoto; Arlin B Rogers; Betty L Slagle; Jack R Wands
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

9.  Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells.

Authors:  Ya-Wen Chen; Victor Boyartchuk; Brian C Lewis
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

10.  [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].

Authors:  M A Kern; K Breuhahn; M Schuchmann; P Schirmacher
Journal:  Pathologe       Date:  2007-07       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.